Alembic aims for US rebound with new launches

Alembic Pharmaceuticals plans to launch 20 new products in the US market in FY24, including oncology and non-oncology injectables, derma, and ophthalmic products. The launches will be facilitated by the newly USFDA-compliant facilities. The company also plans to take advantage of drug shortages in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rpx4IfS
via IFTTT